In This Issue
Journal: Cancer Discovery (2022)

In This Issue| September 02 2022 In This Issue Author & Article Information Online ISSN: 2159-8290 Print ISSN: 2159-8274 ©2022 American Association for Cancer Research2022American Association for Cancer Research Cancer Discov (2022) 12 (9): 2007–2009. https://doi.org/10.1158/2159-8290.CD-12-9-ITI Related Content A commentary has been published: AACR Project GENIE: 100,000 Cases and Beyond A commentary has been published: Common Trajectories of Highly Effective CD19-Specific CAR T Cells Identified by Endogenous T-cell Receptor Lineages A commentary has been published: Drug-Induced Epigenomic Plasticity Reprograms Circadian Rhythm Regulation to Drive Prostate Cancer toward Androgen Independence View more A commentary has been published: Coordinated Transcriptional and Catabolic Programs Support Iron-Dependent Adaptation to RAS–MAPK Pathway Inhibition in Pancreatic Cancer A commentary has been published: Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study A commentary has been published: A Therapeutically Actionable Protumoral Axis of Cytokines Involving IL-8, TNFα, and IL-1β A commentary has been published: PRC2-Inactivating Mutations in Cancer Enhance Cytotoxic Response to DNMT1-Targeted Therapy via Enhanced Viral Mimicry A commentary has been published: NCOA4-Mediated Ferritinophagy Is a Pancreatic Cancer Dependency via Maintenance of Iron Bioavailability for Iron–Sulfur Cluster Proteins A commentary has been published: SMYD3 Impedes Small Cell Lung Cancer Sensitivity to Alkylation Damage through RNF113A Methylation–Phosphorylation Cross-talk View less Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Tools Icon Tools Get Permissions Cite Icon Cite Search Site Article Versions Icon Versions Version of Record September 2 2022 Citation In This Issue. Cancer Discov 1 September 2022; 12 (9): 2007–2009. https://doi.org/10.1158/2159-8290.CD-12-9-ITI Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest Search Advanced Search Using data from the over 100,000 patients currently included in the AACR Project GENIE registry, Pugh and colleagues performed updated comparisons to both The Cancer Genome Atlas and NCI-MATCH and demonstrated important differences that reflect the clinical context of the sequencing represented in GENIE. Importantly, the overall size of GENIE allowed for characterization of drug resistance mechanisms and rare populations, and the comparison with NCI-MATCH demonstrates the ability to use GENIE to provide a data-driven projection of trial enrollment and ultimately can be used to determine when populations are so rare that a trial may not be feasible. See article, p. 2044. The α-subunit–specific PI3K inhibitor alpelisib is an active agent in advanced breast cancer, but the clinical utility and biomarkers for patient selection are poorly defined in heavily pretreated disease. Savas, Lo, and colleagues conducted a phase II trial of alpelisib monotherapy in advanced breast cancer showing, in... You do not currently have access to this content.